Clinical trial • Infectious Disease
Clinical trial in Plasmodium falciparum malaria
Clinical trial for Plasmodium falciparum malaria. 20 participants.
Overview
- Trial Therapeutic Area
- Infectious Disease
- Trial Disease
- Plasmodium falciparum malaria
Key dates
- Initial CTIS Submission Date
- 07-11-2025
- First CTIS Authorization Date
- 09-03-2026
Trial design
Clinical trial across 1 site in Netherlands.
- Target Sample Size
- 20
Recruitment
- Planned Sample Size
- 20
- Recruitment Window Months
- 8
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 20
Netherlands
- Earliest CTIS Part Ii Submission Date
- 04-03-2026
- Latest Decision Or Authorization Date
- 09-03-2026
- Processing Time Days
- 5
- Number Of Sites
- 1
- Number Of Participants
- 20
Sites
- Site Name
- LUMC
- Department Name
- LUCID
- Principal Investigator Name
- Meta Roestenberg
- Principal Investigator Email
- m.roestenberg@lumc.nl
- Contact Person Name
- Meta Roestenberg
- Contact Person Email
- m.roestenberg@lumc.nl
- Number Of Participants
- 20
Sponsor
Primary sponsor
- Full Name
- Leids Universitair Medisch Centrum (LUMC)
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Related trials
Other published trials that may interest you.
- Conditioned medium from a co-culture of M2-macrophages and fat-derived mesenchymal cells for Acute respiratory distress syndrome (ARDS) | SARS-CoV-2 infection | Influenza A infection | Influenza B infection | Respiratory syncytial virus (RSV) infection
- ACICLOVIR for Recurrent herpes labialis | Herpes simplex labialis
- AMIKACIN SULFATE for Sepsis | Neutropenia
- LENACAPAVIR, ISLATRAVIR for HIV-1 infection
- piperacillin sodium, tazobactam sodium for Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae severe infection